SML2807

Sigma-Aldrich

JP4-039

≥98% (HPLC)

Sinónimos:
4-(3E,5S)-5-(1,1-Dimethylethoxy)carbonylamino-7-methyl-1-oxo-3-octen-1-ylamino-2,2,6,6-tetramethyl-1-piperidinyloxy, JP 4-039
Empirical Formula (Hill Notation):
C23H42N3O4
Número de CAS:
Peso molecular:
424.60
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

assay

≥98% (HPLC)

form

powder

color

faint yellow to dark orange

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(C/C=C/C@@H(NC(OC(C)(C)C)=O)CC(C)C)NC1CC(C)(C)N(O)C(C)(C)C1

Biochem/physiol Actions

JP4-039 is an electron-/reactive oxygen species (ROS)-scavenging GS-nitroxide composed of 4-amino-TEMPO and a truncated gramicidin S (GS) mitochrondria-targeting sequence. JP4-039 is a superior irradiation mitigator than XJB-5-131 (33% vs. 20% mice survial rate on day 35 with respective compound; 23.6 μmol/kg iv. 24 hr post 9.5 Gy whole body irradiation), while displaying weaker anti-ferroptotic potency (EC50 = 3.58 μM/1.27 μM against 10 μM erastin-/2 μM RSL3-induced HT-1080 ferroptosis vs. 114 nM/68 nM with XJB-5-131) due to lower lipophilicity & mitochondria enrichment. Typical dosing range: 40 nM-10 μM in cultures and 10-20 mg/kg in mice (im., ip., iv.) in vivo.

WGK Germany

WGK 3

Tanja Krainz et al.
ACS central science, 2(9), 653-659 (2016-10-12)
Discovering compounds and mechanisms for inhibiting ferroptosis, a form of regulated, nonapoptotic cell death, has been of great interest in recent years. In this study, we demonstrate the ability of XJB-5-131, JP4-039, and other nitroxide-based lipid peroxidation mitigators to prevent...
Michael W Epperly et al.
In vivo (Athens, Greece), 24(6), 811-819 (2010-12-18)
this study evaluated esophageal radioprotection by the Gramicidin S (GS) derived-nitroxide, JP4-039, a mitochondrial targeting peptide-isostere covalently-linked to 4-amino-Tempo, delivered in a novel swallowed oil-based (F15) formulation. C57BL/6HNsd female mice received intraesophageal F15 formulation containing JP4-039 (4 mg/ml in 100...
Julie P Goff et al.
In vivo (Athens, Greece), 25(3), 315-323 (2011-05-18)
Total-body irradiation (TBI) doses in the range of 2-8 Gy are associated with a drop in peripheral blood counts, decreased bone marrow cellularity, and hematopoietic syndrome. Radiation mitigators must be safe for individuals likely to recover spontaneously. Female C57BL/6HNsd mice...
Michael W Epperly et al.
In vivo (Athens, Greece), 31(2), 159-168 (2017-03-31)
Total-body irradiation and/or administration of chemotherapy drugs in bone marrow transplantation induce cytokines that can suppress engraftment. Fanconi Anemia (FA) patients have a hyperactive responsiveness to the inhibitory cytokine, transforming growth factor-beta (TGF-β). Small molecule radiation mitigator drugs, JP4-039 and...
Malolan S Rajagopalan et al.
In vivo (Athens, Greece), 23(5), 717-726 (2009-09-26)
It was unknown if a mitochondria-targeted nitroxide (JP4-039) could augment potentially lethal damage repair (PLDR) of cells in quiescence. We evaluated 32D cl 3 murine hematopoietic progenitor cells which were irradiated and then either centrifuged to pellets (to simulate PLDR...

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.